Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap - 15/05/26
, Carolin V. Schneider, MD c, Saeed Hamid, MBBS, FRCP d, Faisal Abaalkhail, MD e, fRésumé |
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction-associated steatohepatitis (MASH), are growing global health concerns. In the Middle East, rising rates of obesity and diabetes contribute to an increasing burden of MASLD and MASH. However, countries across the region vary in care models, health care infrastructure, and workforce capacity. Gaps remain in health policy, research infrastructure, and participation in global studies. This review outlines the current landscape of MASH in the Middle East and discusses strategies to strengthen diagnosis, management, and regionally relevant evidence generation.
Le texte complet de cet article est disponible en PDF.Keywords : MASH, Middle East, Fibrosis, Cirrhosis, MASLD
Plan
Vol 30 - N° 2
P. 483-494 - mai 2026 Retour au numéro
Article précédent
- What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
- Lorenzo D’Antiga, Emer Fitzpatrick, Rohit Kohli, Jeffrey B. Schwimmer
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management
- Takashi Kobayashi, Masato Yoneda, Ajay Duseja, Jian-Gao Fan, Alexander Nersesov, Atsushi Nakajima
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?